Cargando…
Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma
Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recur...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637455/ https://www.ncbi.nlm.nih.gov/pubmed/36381868 http://dx.doi.org/10.7759/cureus.30064 |
_version_ | 1784825191450279936 |
---|---|
author | Kawamura, Shin Katsuki, Masahito Kashiwagi, Kenta Koh, Akihito |
author_facet | Kawamura, Shin Katsuki, Masahito Kashiwagi, Kenta Koh, Akihito |
author_sort | Kawamura, Shin |
collection | PubMed |
description | Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recurred despite surgical and chemo-radiological treatment. He had migraine and headache attributed to glioblastoma, but fremanezumab improved both of them. Our case suggested that fremanezumab’s possible efficacy for not only migraine but also headache attributed to intracranial neoplasia. |
format | Online Article Text |
id | pubmed-9637455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-96374552022-11-14 Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma Kawamura, Shin Katsuki, Masahito Kashiwagi, Kenta Koh, Akihito Cureus Pain Management Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recurred despite surgical and chemo-radiological treatment. He had migraine and headache attributed to glioblastoma, but fremanezumab improved both of them. Our case suggested that fremanezumab’s possible efficacy for not only migraine but also headache attributed to intracranial neoplasia. Cureus 2022-10-08 /pmc/articles/PMC9637455/ /pubmed/36381868 http://dx.doi.org/10.7759/cureus.30064 Text en Copyright © 2022, Kawamura et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pain Management Kawamura, Shin Katsuki, Masahito Kashiwagi, Kenta Koh, Akihito Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma |
title | Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma |
title_full | Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma |
title_fullStr | Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma |
title_full_unstemmed | Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma |
title_short | Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma |
title_sort | fremanezumab improved migraine and headache attributed to glioblastoma |
topic | Pain Management |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637455/ https://www.ncbi.nlm.nih.gov/pubmed/36381868 http://dx.doi.org/10.7759/cureus.30064 |
work_keys_str_mv | AT kawamurashin fremanezumabimprovedmigraineandheadacheattributedtoglioblastoma AT katsukimasahito fremanezumabimprovedmigraineandheadacheattributedtoglioblastoma AT kashiwagikenta fremanezumabimprovedmigraineandheadacheattributedtoglioblastoma AT kohakihito fremanezumabimprovedmigraineandheadacheattributedtoglioblastoma |